Literature DB >> 3973388

Demonstration of the interaction of native C1 with monomeric immunoglobulins and C1 inhibitor.

R J Ziccardi.   

Abstract

The association of native C1 with physiologically relevant proteins was studied by ultracentrifugation. 125I-C1 was centrifuged through numerous sucrose density gradients, each of which contained a different concentration of monomeric (19S) IgM throughout the gradient. The s-rate of C1 (16S) increased with increasing IgM input to a maximum of 32S. In the absence of C1q, the C1r2s2 subunit did not bind to the Ig. In gradients containing physiologic concentrations of IgM (1.3 mg/ml) at 0.14 M ionic strength, the observed s-rate of C1 was 21S. In the presence of 13 mg/ml IgG, C1 sedimented with an s-rate of 19S. Thus, under physiologic conditions, a significant fraction of native C1 is reversibly bound to monomeric Ig. SDS-PAGE analyses show that this interaction does not lead to C1 activation. The interaction of native C1 with C1 inhibitor (C1-In) was studied by ultracentrifugation at physiologic ionic strength. Purified 125I-C1-In alone sedimented with an s-rate of 4S. However in the presence of excess native C1, one-third of the C1-In co-sedimented with C1 at a 16S position. For these studies, 100 microM nitrophenylguanidinobenzoate (NPGB) was present throughout the sucrose density gradient to prevent C1 activation during centrifugation. As the concentration of NPGB was increased, the percent of 125I-C1-In at 16S decreased, indicating that C1-In was binding (reversibly) to the C1 active site region(s), which is at least partially accessible in uncleaved C1. In controls, when NPGB was omitted or activated C1 was used, the s-rate of 125I-C1-In was only 12S due to the release of C1rC1s(C1-In)2 from activated C1. Thus, under physiologic conditions native C1 is reversibly bound to C1-In.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3973388

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

2.  C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities.

Authors:  C H Chen; C F Lam; R J Boackle
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

3.  Mechanism of action of anti-C1-inhibitor autoantibodies: prevention of the formation of stable C1s-C1-inh complexes.

Authors:  S He; R B Sim; K Whaley
Journal:  Mol Med       Date:  1998-02       Impact factor: 6.354

4.  Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity.

Authors:  Ebbe Billmann Thorgersen; Judith K Ludviksen; John D Lambris; Georgia Sfyroera; Erik Waage Nielsen; Tom Eirik Mollnes
Journal:  Innate Immun       Date:  2009-08-26       Impact factor: 2.680

5.  Complement 1 inhibitor is a regulator of the alternative complement pathway.

Authors:  H Jiang; E Wagner; H Zhang; M M Frank
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

6.  Angioedema induced by a peptide derived from complement component C2.

Authors:  C J Strang; S Cholin; J Spragg; A E Davis; E E Schneeberger; V H Donaldson; F S Rosen
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

7.  Pharmaceutical Machine Learning: Virtual High-Throughput Screens Identifying Promising and Economical Small Molecule Inhibitors of Complement Factor C1s.

Authors:  Jonathan J Chen; Lyndsey N Schmucker; Donald P Visco
Journal:  Biomolecules       Date:  2018-05-07

Review 8.  Paths reunited: Initiation of the classical and lectin pathways of complement activation.

Authors:  Russell Wallis; Daniel A Mitchell; Ralf Schmid; Wilhelm J Schwaeble; Anthony H Keeble
Journal:  Immunobiology       Date:  2009-09-27       Impact factor: 3.144

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.